THERAPY DOSSIER · th-60f5cb6d9f31

Qingyi pellet (QYT, traditional Chinese herbal formulation)

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00508729 ↗PHASE2/PHASE3unknown

Effect of Traditional Chinese Medicine on Gastrointestinal Function Recovery and Nutrition Support in Severe Acute Pancreatitis (Qingyi granules)

Pancreatitis, Acute Necrotizing

Enrolment: 300 · Results not recorded

NCT00506337 ↗PHASE2/PHASE3unknown

Evaluation of Effect of Integrated Treatment by Traditional Chinese and Western Medicine for Severe Acute Pancreatitis (Qingyi granules)

Pancreatitis, Acute Necrotizing

Enrolment: 300 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31545248 ↗2019Reported benefit

Proteomic analysis of therapeutic effects of Qingyi pellet on rodent severe acute pancreatitis-associated lung injury.

RatOtherSprague-Dawleymale

Model: Severe acute pancreatitis-associated lung injury (SAP-ALI) rat model

Qingyi pellet reversed the direction of change of nine lung proteins altered by severe acute pancreatitis, down-regulating seven proteins including alpha-2-macroglobulin, cathepsin S, RAP-1A, integrin beta, protein phosphatase 2A, ICAM-1 and p38, and up-regulating adapter molecule Crk and stathmin.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…